Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACT/rilparencel in Type 2 Diabetes and Chronic Kidney Disease
NCT05099770Phase 3Active, not recruiting
- Sponsor
- ProKidney
- Start
- Jan 2022
- Primary completion
- Dec 2029
- Modality
- Adoptive Cell Transfer
- Countries
- 4
01
Overview
A Phase 3 trial of rilparencel in chronic kidney disease (CKD), sponsored by ProKidney. Started Jan 2022; status: active, not recruiting.
02
Drugs
rilparencel
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05099770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099770.